Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer

Scott D. Ramsey, Carol M. Moinpour, Laura C. Lovato, John J. Crowley, Patra Grevstad, Cary A. Presant, Saul E. Rivkin, Karen Kelly, David R Gandara

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background: It is increasingly important to have timely information about the economic impact of new cancer therapies in today's cost-conscious environment. Nearly 170 000 people are diagnosed with lung cancer annually in the United States. We performed an economic analysis alongside Southwest Oncology Group Trial S9509 to estimate the cost-effectiveness of cisplatin plus vinorelbine versus carboplatin plus paclitaxel for patients with advanced non-small-cell lung cancer. There were no statistically significant differences in survival or cancer-related quality of life between the treatment arms. Methods: Use of both protocol and nonprotocol lung cancer-related health care was tracked for 24 months from the initiation of therapy. To determine expenditures, nationally standardized costs were applied to each type of health care service used, and these were summed over time. Lifetime expenditures and 95% confidence intervals (CIs) for each arm of the trial were calculated with the use of a multivariate regression technique that accounts for censoring. Student's t tests were used to compare the difference in costs between the arms. All statistical tests were two-sided. Results: Cancer-related health care costs over the period of observation averaged $40292 (95% CI = $36226 to $44359) for patients in the cisplatin plus vinorelbine arm versus $48940 (95% CI = $44674 to $53208) for patients in the carboplatin plus paclitaxel arm (P = .004), with a mean difference of $8648 (95% CI = $2634 to $14662). Protocol chemotherapy drugs and medical procedures costs were statistically significantly higher in the paclitaxel arm (P = .0003 and P<.0001, respectively), whereas protocol chemotherapy delivery costs were statistically significantly higher in the vinorelbine arm (P<.0001). There was no difference between the arms in costs for blood products, supportive care medications, nonprotocol-related inpatient or outpatient care, and nonprotocol chemotherapy. Conclusions: Treatment with carboplatin plus paclitaxel is substantially and statistically significantly more expensive than treatment with cisplatin plus vinorelbine. The majority of the cost difference is due to the additional cost of the protocol chemotherapy (approximately $12000). Notable differences in costs of downstream health care were not apparent.

Original languageEnglish (US)
Pages (from-to)291-297
Number of pages7
JournalJournal of the National Cancer Institute
Volume94
Issue number4
StatePublished - Feb 20 2002

Fingerprint

Carboplatin
Non-Small Cell Lung Carcinoma
Economics
Costs and Cost Analysis
Paclitaxel
Confidence Intervals
Cisplatin
Drug Therapy
Health Expenditures
Health Care Costs
Lung Neoplasms
Delivery of Health Care
Therapeutics
Neoplasms
TP protocol
vinorelbine
Ambulatory Care
Health Services
Cost-Benefit Analysis
Inpatients

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. / Ramsey, Scott D.; Moinpour, Carol M.; Lovato, Laura C.; Crowley, John J.; Grevstad, Patra; Presant, Cary A.; Rivkin, Saul E.; Kelly, Karen; Gandara, David R.

In: Journal of the National Cancer Institute, Vol. 94, No. 4, 20.02.2002, p. 291-297.

Research output: Contribution to journalArticle

Ramsey, SD, Moinpour, CM, Lovato, LC, Crowley, JJ, Grevstad, P, Presant, CA, Rivkin, SE, Kelly, K & Gandara, DR 2002, 'Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer', Journal of the National Cancer Institute, vol. 94, no. 4, pp. 291-297.
Ramsey, Scott D. ; Moinpour, Carol M. ; Lovato, Laura C. ; Crowley, John J. ; Grevstad, Patra ; Presant, Cary A. ; Rivkin, Saul E. ; Kelly, Karen ; Gandara, David R. / Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. In: Journal of the National Cancer Institute. 2002 ; Vol. 94, No. 4. pp. 291-297.
@article{b9017bcbee6249dca239b0ae4fb571d8,
title = "Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer",
abstract = "Background: It is increasingly important to have timely information about the economic impact of new cancer therapies in today's cost-conscious environment. Nearly 170 000 people are diagnosed with lung cancer annually in the United States. We performed an economic analysis alongside Southwest Oncology Group Trial S9509 to estimate the cost-effectiveness of cisplatin plus vinorelbine versus carboplatin plus paclitaxel for patients with advanced non-small-cell lung cancer. There were no statistically significant differences in survival or cancer-related quality of life between the treatment arms. Methods: Use of both protocol and nonprotocol lung cancer-related health care was tracked for 24 months from the initiation of therapy. To determine expenditures, nationally standardized costs were applied to each type of health care service used, and these were summed over time. Lifetime expenditures and 95{\%} confidence intervals (CIs) for each arm of the trial were calculated with the use of a multivariate regression technique that accounts for censoring. Student's t tests were used to compare the difference in costs between the arms. All statistical tests were two-sided. Results: Cancer-related health care costs over the period of observation averaged $40292 (95{\%} CI = $36226 to $44359) for patients in the cisplatin plus vinorelbine arm versus $48940 (95{\%} CI = $44674 to $53208) for patients in the carboplatin plus paclitaxel arm (P = .004), with a mean difference of $8648 (95{\%} CI = $2634 to $14662). Protocol chemotherapy drugs and medical procedures costs were statistically significantly higher in the paclitaxel arm (P = .0003 and P<.0001, respectively), whereas protocol chemotherapy delivery costs were statistically significantly higher in the vinorelbine arm (P<.0001). There was no difference between the arms in costs for blood products, supportive care medications, nonprotocol-related inpatient or outpatient care, and nonprotocol chemotherapy. Conclusions: Treatment with carboplatin plus paclitaxel is substantially and statistically significantly more expensive than treatment with cisplatin plus vinorelbine. The majority of the cost difference is due to the additional cost of the protocol chemotherapy (approximately $12000). Notable differences in costs of downstream health care were not apparent.",
author = "Ramsey, {Scott D.} and Moinpour, {Carol M.} and Lovato, {Laura C.} and Crowley, {John J.} and Patra Grevstad and Presant, {Cary A.} and Rivkin, {Saul E.} and Karen Kelly and Gandara, {David R}",
year = "2002",
month = "2",
day = "20",
language = "English (US)",
volume = "94",
pages = "291--297",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer

AU - Ramsey, Scott D.

AU - Moinpour, Carol M.

AU - Lovato, Laura C.

AU - Crowley, John J.

AU - Grevstad, Patra

AU - Presant, Cary A.

AU - Rivkin, Saul E.

AU - Kelly, Karen

AU - Gandara, David R

PY - 2002/2/20

Y1 - 2002/2/20

N2 - Background: It is increasingly important to have timely information about the economic impact of new cancer therapies in today's cost-conscious environment. Nearly 170 000 people are diagnosed with lung cancer annually in the United States. We performed an economic analysis alongside Southwest Oncology Group Trial S9509 to estimate the cost-effectiveness of cisplatin plus vinorelbine versus carboplatin plus paclitaxel for patients with advanced non-small-cell lung cancer. There were no statistically significant differences in survival or cancer-related quality of life between the treatment arms. Methods: Use of both protocol and nonprotocol lung cancer-related health care was tracked for 24 months from the initiation of therapy. To determine expenditures, nationally standardized costs were applied to each type of health care service used, and these were summed over time. Lifetime expenditures and 95% confidence intervals (CIs) for each arm of the trial were calculated with the use of a multivariate regression technique that accounts for censoring. Student's t tests were used to compare the difference in costs between the arms. All statistical tests were two-sided. Results: Cancer-related health care costs over the period of observation averaged $40292 (95% CI = $36226 to $44359) for patients in the cisplatin plus vinorelbine arm versus $48940 (95% CI = $44674 to $53208) for patients in the carboplatin plus paclitaxel arm (P = .004), with a mean difference of $8648 (95% CI = $2634 to $14662). Protocol chemotherapy drugs and medical procedures costs were statistically significantly higher in the paclitaxel arm (P = .0003 and P<.0001, respectively), whereas protocol chemotherapy delivery costs were statistically significantly higher in the vinorelbine arm (P<.0001). There was no difference between the arms in costs for blood products, supportive care medications, nonprotocol-related inpatient or outpatient care, and nonprotocol chemotherapy. Conclusions: Treatment with carboplatin plus paclitaxel is substantially and statistically significantly more expensive than treatment with cisplatin plus vinorelbine. The majority of the cost difference is due to the additional cost of the protocol chemotherapy (approximately $12000). Notable differences in costs of downstream health care were not apparent.

AB - Background: It is increasingly important to have timely information about the economic impact of new cancer therapies in today's cost-conscious environment. Nearly 170 000 people are diagnosed with lung cancer annually in the United States. We performed an economic analysis alongside Southwest Oncology Group Trial S9509 to estimate the cost-effectiveness of cisplatin plus vinorelbine versus carboplatin plus paclitaxel for patients with advanced non-small-cell lung cancer. There were no statistically significant differences in survival or cancer-related quality of life between the treatment arms. Methods: Use of both protocol and nonprotocol lung cancer-related health care was tracked for 24 months from the initiation of therapy. To determine expenditures, nationally standardized costs were applied to each type of health care service used, and these were summed over time. Lifetime expenditures and 95% confidence intervals (CIs) for each arm of the trial were calculated with the use of a multivariate regression technique that accounts for censoring. Student's t tests were used to compare the difference in costs between the arms. All statistical tests were two-sided. Results: Cancer-related health care costs over the period of observation averaged $40292 (95% CI = $36226 to $44359) for patients in the cisplatin plus vinorelbine arm versus $48940 (95% CI = $44674 to $53208) for patients in the carboplatin plus paclitaxel arm (P = .004), with a mean difference of $8648 (95% CI = $2634 to $14662). Protocol chemotherapy drugs and medical procedures costs were statistically significantly higher in the paclitaxel arm (P = .0003 and P<.0001, respectively), whereas protocol chemotherapy delivery costs were statistically significantly higher in the vinorelbine arm (P<.0001). There was no difference between the arms in costs for blood products, supportive care medications, nonprotocol-related inpatient or outpatient care, and nonprotocol chemotherapy. Conclusions: Treatment with carboplatin plus paclitaxel is substantially and statistically significantly more expensive than treatment with cisplatin plus vinorelbine. The majority of the cost difference is due to the additional cost of the protocol chemotherapy (approximately $12000). Notable differences in costs of downstream health care were not apparent.

UR - http://www.scopus.com/inward/record.url?scp=0037138736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037138736&partnerID=8YFLogxK

M3 - Article

C2 - 11854391

AN - SCOPUS:0037138736

VL - 94

SP - 291

EP - 297

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -